Patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a life-threatening and progressive form of heart failure, are finding treatment with the drug tafamidis.

Among the largest programs in the world for pulmonary hypertension, the Pulmonary Hypertension Centers of NewYork-Presbyterian manage some of the most complicated and sickest patients with this rare, progressive cardiopulmonary disease.

The research of Andrew R. Marks has contributed fundamental insights into the molecular mechanisms regulating contraction of normal and failing cardiac muscle, molecular triggers of cardiac arrhythmias, and coronary artery in-stent restenosis.

Steven O. Marx, MD and Geoffrey S. Pitt, together and individually, are making major contributions to understanding the role of ion channels in normal and pathological conditions in the heart.

Cardiologists, interventional cardiologists, and cardiac surgeons at NewYork-Presbyterian bring their expertise to bear in collaborations that allow the details of the patient’s disease to dictate the best treatment.

List of Current Clinical Trials for Transcatheter Mitral Valve Repair